Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study

American Journal of Hematology

Volumn 88, Issue 2, 2013, Pages 130-134

  Merkel, Drorit ^a   Filanovsky, Kalman ^b   Gafter Gvili, Anat ^a   Vidal, Liat ^a   Aviv, Ariel ^c   Gatt, Moshe E ^d   Silbershatz, Itay ^e   Herishanu, Yair ^f   Arad, Ariela ^g   Tadmor, Tamar ^h,i   Dally, Najib ^j   Nemets, Anatoly ^k   Rouvio, Ory ^l   Ronson, Aharon ^m   Herzog Tzarfati, Katrin ⁿ   Akria, Luiza ^o   Braester, Andrei ^o   Hellmann, Ilana ^p   Yeganeh, Shay ^q   Nagler, Arnon ^a   Leiba, Ronit ^r   Mittelman, Moshe ^a   Ofran, Yishai ^i,s   more..

^a TEL AVIV UNIVERSITY   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c HAEMEK MEDICAL CENTER   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e WOLFSON MEDICAL CENTER   (Israel)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g LANIADO HOSPITAL   (Israel)

^h BNAI ZION MEDICAL CENTER   (Israel)

ⁱ TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^j Rebecca Sieff Government Hospital   (Israel)

^k BARZILAI MEDICAL CENTER   (Israel)

^l BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^m SHAARE ZEDEK MEDICAL CENTER   (Israel)

ⁿ ASSAF HAROFEH MEDICAL CENTER   (Israel)

^o WESTERN GALILEE HOSPITAL   (Israel)

^p MEIR MEDICAL CENTER   (Israel)

^q Poriya Hospital   (Israel)

^r Quality of Care Unit   (Israel)

^s Rambam Health Care Campus ^*  (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; HEMOGLOBIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CYTOGENETICS; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CHROMOSOME ABERRATIONS; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; INCIDENCE; INFECTION; ISRAEL; LEUKEMIA, MYELOID, ACUTE; MALE; METHYLATION; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA;

EID: 84872924343     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23368     Document Type: Article

References (26)

1. Toma A, Fenaux P, Dreyfus F, et al. Infections in myelodysplastic syndromes. Haematologica 2012;97:1459-1470.
2. Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: Azacitidine compared with low dose ara-C. Br J Haematol 2010;149:244-249.
3. Breccia M, Loglisci G, Salaroli A, et al. 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. Leuk Lymphoma 2012;53:1558-1560.
4. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (>/= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010;76:218-227.
5. Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol 2010;85:130-138.
6. Fenaux P, Bowen D, Gattermann N, et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion. Leuk Res 2010;34:1410-1416.
7. Tong WG, Quintas-Cardama A, Kadia T, et al. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 2012.
8. Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-411.
9. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
10. Martinez-Frances A. Adverse effects of azacitidine: Onset, duration, and treatment. Adv Ther 2011;28 (Suppl 4):1-5.
11. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-569.
12. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
13. Garcia-Manero G. Treatment of higher-risk myelodysplastic syndrome. Semin Oncol 2011;38:673-681.
14. Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: A multicenter phase I/II study. Leuk Lymphoma 2012;53:110-117.
15. Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012;118:1014-1022.
16. Garcia-Manero G. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:490-498.
17. Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011;29:2521-2527.
18. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52:e56-e93.
19. Lee JH, Lee KH, Kim DY, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res 2011;35:499-503.
20. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
21. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-995.
22. Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol 2011;38:635-647.
23. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009;113:6296-6303.
24. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012;366:1090-1098.
25. Qu S, Xu Z, Zhang Y, et al. Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: Results of a single-center study. Leuk Lymphoma 2012;53:940-946.
26. van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011;155:599-606.